Rezetapopt demonstrated a 44.4% overall response rate and durable responses lasting over eight months in patients with ...
Add Yahoo as a preferred source to see more of our stories on Google. A Gloucestershire police officer is set to complete a ...
A global team of doctors and researchers are using AI to better improve the treatment and survival rates of women with ...
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion ...
The average age for an ovarian cancer diagnosis is after 63 ...
A Gnadenhutten ovarian cancer survivor marked two years since treatment by completing a half-marathon at the Run for Home in ...
In this video, Ursula A. Matulonis, MD, discusses results from the RAMP-201 trial of combination avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer with KRAS ...
In this video, Ursula A. Matulonis, MD, discusses a study assessing letrozole alone compared with standard chemotherapy followed by letrozole maintenance in patients with low-grade serous ovarian, ...
MedPage Today on MSN
Advanced Ovarian Cancer Responds to Claudin-Targeted Drug in Preliminary Trial
Partial responses in half of patients with platinum-resistant disease, as crowded ADC list ...
The Jackson community is supporting Crazy Cowboy owner Liz Wiginton with a GoFundMe and restaurant visits after a stage 4 ...
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced ...
New AACR data highlight stenoparib’s potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results